Initial results of clinical trial with a new left ventricular assist device (LVAD) providing synchronous pulsatile flow

Initial results of clinical trial with a new left ventricular assist device (LVAD) providing synchronous pulsatile flow

A multicentric European Clinical Study is ongoing to evaluate safety and efficacy of a new pulsatile implantable LVAD (BestBeat), smaller and lighter than similar devices, capable of providing synchronous and counterpulsating flow with respect to the LV of end-stage heart failure patients. Prelimina...

Full description

Saved in:
Bibliographic Details
Published in:International journal of artificial organs Vol. 32; no. 6; pp. 344 - 353
Main Authors: Gazzoli, Fabrizio, Viganò, Mario, Pagani, Francesco, Alloni, Alessia, Silvaggio, Giuseppe, Panzavolta, Marco, El Banayosy, Aly, Koerfer, Reiner, Morshuis, Michiel, Pavie, Alain, Leprince, Pascal, Glauber, Mattia, Del Sarto, Paolo, Haxhademi, Dorela, Vitali, Ettore, Russo, Claudio F, Scuri, Silvia
Format: Journal Article
Language:English
Published: United States 01-06-2009
Subjects:
Bilirubin - blood
Biomarkers - blood
Blood Urea Nitrogen
Creatine - blood
Equipment Design
Europe
Heart Failure - blood
Heart Failure - mortality
Heart Failure - physiopathology
Heart Failure - therapy
Heart Transplantation
Heart-Assist Devices - adverse effects
Humans
Male
Middle Aged
Pilot Projects
Pulsatile Flow
Recovery of Function
Time Factors
Treatment Outcome
Ventricular Function, Left
Europe
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A multicentric European Clinical Study is ongoing to evaluate safety and efficacy of a new pulsatile implantable LVAD (BestBeat), smaller and lighter than similar devices, capable of providing synchronous and counterpulsating flow with respect to the LV of end-stage heart failure patients. Preliminary clinical results are reported. The new BestBeat LVAD was used, consisting of an implantable pulsatile blood pump, electromechanically driven by a ball screw mechanism, and a wearable electronic controller and power sources. The clinical trial was conducted at 5 european centers. Adult patients affected by CHF in NYHA Class IV despite optimized medical treatment were enrolled. The primary study endpoint was survival at 90 days. Further study endpoints were maintenance of adequate LVAD pump flow and a minimum rate of adverse events during support. As of June 2008, 6 patients received the implant. Cumulative support time was 3.7 years, median support time 176 days. All patients who completed the study survived except for one, who died after 48 days, due to combined infection and cerebrovascular accident. Another two patients died: one from intracranial bleeding 113 days after implant, and one from septic shock after 123 days. Hemodynamic improvement with CI>2.0 l/min/m2 and recovery of end-organ function expressed by consistent improvement of BUN, creatinine and bilirubin were reached in all patients. No device failure was observed. There was no bleeding requiring re-exploration, no hemolysis and only two device-related infections (both in one patient). Neurologic events were reported, the most serious ones occurring in patients with pre-implant respiratory and kidney failure. Three patients were discharged home. Two patients were successfully transplanted, one after 6 months and one after 13 months on device. Good performance and efficacy of the device were observed; the endpoints of the study were achieved, and its safety was consistent with expectations. The ongoing study will allow further conclusions to be drawn.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0391-3988
1724-6040
DOI:10.1177/039139880903200605